• Penumbra, Inc. recently reported 90-day results from its STORM-PE randomized trial, showing that computer assisted vacuum thrombectomy plus anticoagulation delivered superior functional outcomes and comparable safety versus anticoagulation alone in patients with intermediate-high risk pulmonary embolism.
• The trial’s Level 1 evidence around improved walking distance and recovery of pre-embolism functional status could influence future treatment guidelines and strengthen clinical adoption of Penumbra’s CAVT technology.
• We’ll now examine how these strong STORM-PE functional outcomes, particularly the improved six-minute walk distance, may reshape Penumbra’s investment narrative.

Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

Penumbra Investment Narrative Recap

To own Penumbra, you need to believe that its thrombectomy platforms can stay clinically relevant and justify premium pricing in a competitive device market. The STORM PE 90 day data supports the near term catalyst around CAVT adoption by adding Level 1 evidence on functional recovery, while also reducing the trial outcome risk that previously hung over the story. The main near term risk remains whether competing technologies or pricing pressure blunt the commercial impact of this trial.

The most directly related prior development is the October and November 2025 STORM PE data presentations, which first highlighted right heart strain reduction and early functional gains with CAVT plus anticoagulation. The new 90 day results build on that earlier signal with more granular functional metrics and confirm the safety profile over a longer follow up. Together, these releases create a tighter clinical package that could matter for future guideline discussions and procedure growth.

Yet investors also need to be aware that if hospitals, payers or guideline committees move more slowly than expected on adopting CAVT for PE...

Penumbra's narrative projects $2.0 billion revenue and $304.1 million earnings by 2029. This implies 13.3% yearly revenue growth and an earnings increase of about $126 million from $177.7 million today.

Uncover how Penumbra's forecasts yield a $365.79 fair value, a 10% upside to its current price.

Exploring Other Perspectives

While consensus already looked for revenue to reach about US$2.0 billion and earnings near US$338 million, the most optimistic analysts lean harder on rapid CAVT adoption and could be too confident that hospitals will quickly change PE protocols after STORM PE, so it is worth comparing how their thesis stacks up against slower adoption scenarios.

Explore 3 other fair value estimates on Penumbra - why the stock might be worth 46% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Penumbra research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Penumbra research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Penumbra's overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
• Capitalize on the AI infrastructure supercycle with our selection of the 37 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.